News

Transitions Optical has been named a recipient of the Gallup Great Workplace of the Year Award for the second consecutive year.

People can enter to win prizes in Vistakon?s Acuvue 1-Day Contest through May 23 by submitting a photo and a one-sentence caption about their aspirations at www.facebook.com/acuvue; see the site for details.

Prevent Blindness America (PBA) has received a grant from the Allergan Foundation to enable the organization to develop a Spanish language version of its online Diabetic Eye Disease Educator Program.

Carl Kupfer, MD, who directed the National Eye Institute (NEI) of the National Institutes of Health (NIH) for 30 years, died April 7 after a long illness.

OCuSOFT officially kicked off construction of its new corporate headquarters in Rosenberg, TX, with an April 13 groundbreaking ceremony.

The Bascom Palmer Eye Institute (BPEI) of the University of Miami Miller School of Medicine and Keio University School of Medicine in Tokyo have launched a Japan Eye Rescue Mission to assist that country with recovery from the Tohoku-Pacific Ocean Earthquake.

The Cornea Research Foundation of America is conducting a national clinical study comparing visual results, patient satisfaction, and quality of life issues as they relate to LASIK and contact lenses.

The length of the ragweed season at latitudes above 44 degrees North ?which includes many states in the midwestern and northeastern U.S. ? has increased by as much as 13 to 27 days since 1995, according to a study published in the Proceedings of the National Academy of Sciences.

PixelOptics and Midland Laboratories of St. Louis, MO, have signed a distribution agreement that makes Midland Laboratories part of the emPower limited lab network in the United States.

Vision-Ease Lens (VEL) has reinstated the availability of nearly all of its product styles, 17 months after a fire at the company?s manufacturing facility in Jakarta, Indonesia, led to a temporary suspension of some styles. No employees were injured in the November, 2009 fire, but production was halted at the facility while it was rebuilt.

Careful use of anti-vascular endothelial growth factor agents for the treatment of age-related macular degeneration is acceptable, but physicians should be alert for exceptions to the expected outcome.

Some practical advice and common-sense tips can help clinicians stay abreast of developments and possible malpractice cases.

Most eye-care practitioners are unlikely to read any journal cover to cover, and perhaps they may consider meibomian gland dysfunction underwhelming as a topic at a time when there are a number of exciting developments in vision research.

Results from a phase III study investigating intravitreal ranibizumab for the treatment of DME show that the anti-vascular endothelial growth factor agent was well-tolerated and met its primary efficacy endpoint.

The recently published report from the International Workshop on Meibomian Gland Dysfunction provides an evidence-based review of current knowledge about meibomian gland structure and function in health and disease, offers an idea bank for researchers with an interest in the field, and provides practical guidance to clinicians on the evaluation and management of a very common disorder.

After enduring several disappointing drug trials of treatments that once held promise for dry eye and cystic fibrosis, Inspire Pharmaceuticals will become part of Merck & Co. Inc. in a $430 million acquisition.

If you feel that you have flow issues in your office, stop being the technician's safety valve for poor behavior.

A new quinazolinone compound represents a novel approach to management of choroidal neovascularization.

Periocular injections of steroids improve active inflammation and macular edema in most patients with uveitis.

Sustained release fluocinolone acetonide has the potential to become an effective long-term treatment for DME.

Measure your inventory turns monthly.

The author discusses how MGD is a major source of morbidity and decreased quality of life for patients.

The pivotal study of a sustained-release dexamethasone intravitreal implant showed that it was a safe, effective option for the treatment of noninfectious intermediate and posterior uveitis.

In patients who have not undergone previous treatment, bevacizumab appears to be a safe and effective treatment for exudative age-related macular degeneration.

The key success factor for turning ideas into reality is planning.

Most aspects of ocular trauma are unique when practicing in a combat environment.

A single intravitreal injection of ocriplasmin is safe, effective, well-tolerated, and is the first pharmacologic treatment for symptomatic vitreomacular adhesion.

On March 16, LENSAR Inc. received 510 (k) clearance from the FDA to market its femtosecond laser system for lens fragmentation in addition to anterior capsulotomy during cataract surgery.